While the exact glycosylation sites of NLRP3 have not been fully elucidated, studies suggest that glycosylation may influence its activity and contribute to the inflammatory response in MASLD [94]. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.